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Abstract
Background: In clinical practice, physicians often need to change the antipsychotic medications they give to patients because
of an inadequate response or the presence of unacceptable or unsafe side effects. However, there is a lack of consensus in the
field as to the optimal switching strategy for antipsychotics, especially with regards to the speed at which the dose of the previous
antipsychotic should be reduced. This paper assesses the short-term results of strategies for the discontinuation of olanzapine
when initiating risperidone.
Methods: In a 6-week, randomized, open-label, rater-blinded study, patients with schizophrenia or schizoaffective disorder, on
a stable drug dose for more than 30 days at entry, who were intolerant of or exhibiting a suboptimal symptom response to more
than 30 days of olanzapine treatment, were randomly assigned to the following switch strategies (common risperidone initiation
scheme; varying olanzapine discontinuation): (i) abrupt strategy, where olanzapine was discontinued at risperidone initiation; (ii)
gradual 1 strategy, where olanzapine was given at 50% entry dose for 1 week after risperidone initiation and then discontinued;
or (iii) gradual 2 strategy, where olanzapine was given at 100% entry dose for 1 week, then at 50% in the second week, and then
discontinued.
Results: The study enrolled 123 patients on stable doses of olanzapine. Their mean age was 40.3 years and mean (± standard
deviation (SD)) baseline Positive and Negative Syndrome Scale (PANSS) total score of 75.6 ± 11.5. All-cause treatment
discontinuation was lowest (12%) in the group with the slowest olanzapine dose reduction (gradual 2) and occurred at half the
discontinuation rate in the other two groups (25% in abrupt and 28% in gradual 1). The relative risk of early discontinuation was
0.77 (confidence interval 0.61–0.99) for the slowest dose reduction compared with the other two strategies. After the
medication was changed, improvements at endpoint were seen in PANSS total score (-7.3; p < 0.0001) and in PANSS positive
(-3.0; p < 0.0001), negative (-0.9; p = 0.171) and anxiety/depression (-1.4; p = 0.0005) subscale scores. Severity of movement
disorders and weight changes were minimal.
Conclusion: When switching patients from olanzapine to risperidone, a gradual reduction in the dose of olanzapine over 2
weeks was associated with higher rates of retention compared with abrupt or less gradual discontinuation. Switching via any
strategy was associated with significant improvements in positive and anxiety symptoms and was generally well tolerated.
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Background
In clinical practice the successful treatment of schizophre-
nia may require switching between antipsychotics [1]. The
reasons for changing treatments include inadequate or
complete lack of efficacy, partial compliance or noncom-
pliance with medication, and the presence of adverse
events such as movement disorders, weight gain, somno-
lence, endocrine side effects, and metabolic dysfunction.
The possibility of exacerbation of psychotic symptoms
due to withdrawal of the original antipsychotic before the
new antipsychotic has become effective is a major consid-
eration [1-4]. Conversely, when drugs with long half-lives
are quickly replaced with new treatments, consideration
must be given to possible excessive drug effects.
Guidelines on changing a patient's antipsychotic medica-
tions were provided by a Consensus Study Group in 1996
[5]. Their primary purpose was to assist clinicians in
switching patients from conventional antipsychotics and
from clozapine to the new antipsychotic risperidone. The
guidelines suggest that for hospitalized schizophrenia
patients who are at low risk for psychotic exacerbation or
aggressive or suicidal reactions and who are receiving
antipsychotics other than clozapine, the previous antipsy-
chotic can be withdrawn completely before risperidone is
started. Gradual withdrawal while introducing the other
antipsychotic, however, may be necessary in patients who
are combative or assaultive, those with a history of exacer-
bation of psychotic behavior or suicidal tendencies when
the dose of an antipsychotic was reduced, those receiving
high doses of an antipsychotic, and those receiving cloza-
pine (withdrawal of clozapine has been associated with
withdrawal symptoms and rebound psychosis in some
patients).
A number of studies have assessed methods for changing
treatments in patients with schizophrenia, with varying
results. In 1998, Henderson et al [6] reported the results
of a study of 19 outpatients with treatment-refractory
schizophrenia who were switched from clozapine to olan-
zapine. Olanzapine was started at 5 mg/day and slowly
increased to a maximum of 30 mg/day. After 1 week, cloz-
apine was gradually withdrawn in increments of 25 to 50
mg per week. Eight of the 19 patients were rated as
responders. Seven patients decompensated seriously and
had to be hospitalized and restabilized on clozapine. In
four additional patients, symptoms worsened and the
olanzapine was slowly replaced with clozapine.
In a study of clozapine responders by Littrell et al [7], 20
outpatients were gradually switched from clozapine to
olanzapine. In most cases this was necessitated because of
the adverse events experienced with clozapine. Olanzap-
ine was introduced at 5 mg/day and over a 2-week period
the clozapine dose was reduced in increments of 25 mg
every other day and the olanzapine dose increased. Two of
the patients asked that clozapine be reinstituted because
of symptom exacerbation. In the other patients, symptom
improvement was maintained and the severity of adverse
events was reduced.
Takahashi et al [8,9] have studied treatment changes in
two groups of first-episode schizophrenia patients (inpa-
tients and outpatients) who had failed to respond to treat-
ment. One group was switched from olanzapine to
risperidone (N = 51) and the other from risperidone to
olanzapine (N  = 58). In both studies, the treatment
change was made over a 2-week period during which the
two antipsychotics were gradually replaced. A treatment
response in these 12-week studies was defined as a 20%
reduction in Brief Psychiatric Rating Scale total scores and
a final Clinical Global Impressions (CGI) score of 3
(mildly ill). In the olanzapine-risperidone study, 35% of
the patients were rated as responders and in the risperi-
done-olanzapine study 29% were rated as responders.
Treatment was generally well tolerated. All of the above
studies report a single method employed to change exist-
ing antipsychotic treatment to another antipsychotic.
They do not provide a comparison of methods to change
antipsychotic medication in patients with psychotic ill-
nesses.
The purpose of the present study of patients with schizo-
phrenia or schizoaffective disorder was to evaluate the
efficacy and safety of three strategies for switching antip-
sychotic treatment. This 6-week study was phase 1 of a
longer-term study that addressed weight-control strategies
and the prevalence of the metabolic syndrome in the
patients switched from olanzapine to risperidone [10,11].
The results of phase 2 of the study are also summarized
below.
Methods
The 6-week, open-label, rater-blinded study was designed
to evaluate the efficacy and safety of three strategies for
switching patients with schizophrenia or schizoaffective
disorder from olanzapine to risperidone. The reason for
switching treatments in these patients was the lack of an
adequate clinical response to olanzapine, a body mass
index (BMI) of more than 26 kg/m2 or glucose dysregula-
tion.
Patients were randomly assigned to one of three strategies
for switching from olanzapine to risperidone, abrupt,
gradual 1 (1 week), or gradual 2 (2 weeks), as described
below. Dose adjustments were made in an open-label
fashion; however, all psychiatric assessments were per-
formed by raters blinded to study group assignment. The
trial was conducted in accordance with current Interna-
tional Conference on Harmonisation of TechnicalBMC Medicine 2008, 6:17 http://www.biomedcentral.com/1741-7015/6/17
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Requirements for Registration of Pharmaceuticals for
Human Use (ICH) Good Clinical Practice guidelines and
the Declaration of Helsinki (World Medical Association).
Patients
Patients were recruited at 19 sites in the United States.
Patients were men or women aged 18 to 65 years with a
DSM-IV (Diagnostic and Statistical Manual of Mental Dis-
orders) diagnosis of schizophrenia or schizoaffective dis-
order. Outpatients or stable chronic inpatients could be
included. All patients were to have received a stable dose
of olanzapine for at least 30 days before randomization
and to have had no acute exacerbation of psychotic symp-
toms within the preceding 3 months. To qualify for the
study subjects also had to meet the following criteria: a
Positive and Negative Syndrome Scale (PANSS) [12] total
score of 60 to 120, a BMI above 26 kg/m2, type 2 diabetes,
or laboratory abnormalities related to glucose metabo-
lism, including fasting plasma glucose above 80 mg/dl or
an oral glucose tolerance test 2-hour value above 139 mg/
dl.
Exclusion criteria included previous treatment failure with
risperidone, significant adverse event or sensitivity related
to risperidone, treatment-refractory schizophrenia or
schizoaffective disorder, antipsychotic treatment other
than olanzapine in the 30 days preceding randomization,
mental retardation, substance dependence (DSM-IV), or
serious or unstable concomitant nonpsychiatric medical
illness.
Written informed consent was obtained from each patient
or a relative, guardian, or legal representative.
Medication
The oral dose of risperidone for all patients in all three
strategies was 1 mg twice daily for the first 3 days, fol-
lowed by 2 mg twice daily for the next 4 days. Further dose
adjustments or conversion to a single daily dose could be
made at the end of the first week according to the investi-
gator's judgment. Patients were randomly assigned to dis-
continue olanzapine according to one of the following
three treatment strategies (Figure 1):
(1) Abrupt: olanzapine was discontinued on the day of
risperidone initiation (beginning of week 0).
(2) Gradual 1: the study entry dose of olanzapine was
reduced by half (or as close to half of the starting dose as
possible) on the day of risperidone initiation. The reduced
dose of olanzapine was given for 1 week and then discon-
tinued. The risperidone dose was adjusted as described
above.
(3) Gradual 2: the study entry dose of olanzapine
remained unchanged for the first week of the study while
risperidone was initiated and adjusted as described above.
Dosing schedules for the three strategies Figure 1
Dosing schedules for the three strategies.
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At the end of the first week, the dose of olanzapine was
reduced to half of the study entry dose (or as close to half
of the starting dose as possible) and then discontinued at
the end of the second week.
Any other medication prescribed at a steady dose for at
least 3 weeks before randomization could be continued
during the trial. Any psychotropic medication other than
antipsychotics prescribed before randomization was con-
tinued at the study entry dose throughout the trial. The
only psychotropic medications that could be introduced
during the study period were lorazepam (at most 12 mg/
day) for agitation or anxiety and zolpidem tartrate (at
most 10 mg/day) for insomnia. Medications prescribed
before the trial to control movement disorders could be
discontinued or the dose reduced or increased. Benztro-
pine or propranolol could be initiated to control reversi-
ble movement disorders if clinically necessary.
Assessments
The primary efficacy assessment was the 30-item PANSS,
completed at baseline and weeks 1 through 6. Total
PANSS scores are reported, as well as scores on three
PANSS subscales (positive and negative symptoms and
anxiety/depression). The latter includes the items anxiety,
guilty feelings, tension, and depression (items 2, 3, 4, and
6) from the PANSS general psychopathology subscale.
Additional efficacy assessments were the CGI Change
(CGI-C) and Severity (CGI-S) scales [13]; the Drug Atti-
tude Inventory [14] (DAI-10) completed at baseline and
weeks 1 through 6; and the Global Assessment of Func-
tioning (GAF) [15] at baseline and weeks 1 through 6. The
DAI-10 is a 10-item scale used to assess the patient's view
of the use of psychiatric medications and his or her expe-
rience when taking these drugs.
Weight was measured at baseline and weekly throughout
the study period. Other anthropometric measurements
(height, BMI, slenderness index (height in meters divided
by the sum of the waist and hip width in meters), waist
circumference, waist-to-hip ratio) were made or calcu-
lated at baseline and week 6.
Adverse events and vital signs were recorded at each visit.
Laboratory tests, including hematology, biochemistry,
lipid profile, plasma insulin, glycosylated hemoglobin,
serum leptin, and abbreviated glucose tolerance test, were
performed at baseline and week 6.
Statistical analysis
Safety and efficacy analyses were completed on all rand-
omized patients who received at least one dose of study
medication. All statistical tests were interpreted at the 5%
significance level (two-tailed). Within-group differences
were assessed using a paired t-test. Between-group differ-
ences were assessed using chi-square or Fisher's exact tests
as appropriate for categorical variables and two-way anal-
ysis of variance (ANOVA) with the treatment group and
site as factors for continuous variables. For continuous
change scores, between-group comparisons were calcu-
lated using analysis of covariance (ANCOVA) models,
with the treatment group and site as the fixed effect design
factors and baseline scores as the covariate. No adjust-
ment for multiple comparisons was made.
Results
A total of 123 patients, all outpatients, were enrolled (41
in the Abrupt group, 40 in the Gradual 1 group, and 42 in
the Gradual 2 group). Two patients did not receive any
study medication, 1 in the Abrupt group and 1 in the
Gradual 1 group. The safety data set included all patients
who received at least one dose of study medication. The
intention-to-treat efficacy set included all patients who
received at least one dose of study medication and at least
one completed post-baseline evaluation.
Patient disposition is shown in Table 1 (safety popula-
tion). Significantly more patients in the abrupt (25%) and
Table 1: Patient disposition by treatment group.
Abrupt Gradual 1 Gradual 2 All treatments
Randomized, n 41 40 42 123
Safety population, n 40 39 42 121
Completed, % 75 72 88 79
Discontinued, % 25 28 12 21
Adverse event 5 15 5 8
Withdrew consent 10 8 0 6
Insufficient response 5 0 0 2
Lost to follow-up 0 3 2 2
Noncompliance 0 0 2 1
Other 5 3 2 2
The safety population includes all randomized patients who received at least one dose of study medication. Between-group discontinuation 
differences were not significant (p = 0.1635).BMC Medicine 2008, 6:17 http://www.biomedcentral.com/1741-7015/6/17
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gradual 1 (28%) groups discontinued the study prema-
turely than in the gradual 2 group (12%); relative risk =
0.833, confidence interval (CI) = 0.70–0.99, p = 0.039.
Patient characteristics at baseline were generally similar in
the three groups, with the Abrupt group having slightly
higher BMIs and the Gradual 2 group more likely to have
a diagnosis of schizoaffective disorder (Table 2).
Exposure to medication
Mean (± SD) doses of olanzapine at study entry were 14.4
(± 5.4), 15.5 (± 6.3), and 16.4 (± 7.9) mg/day in the
abrupt, gradual 1, and gradual 2 groups, respectively. The
mean (± SD) modal doses of risperidone at endpoint were
4.3 (± 1.3), 4.9 (± 1.7), and 4.4 (± 1.6) mg/day in the
abrupt, gradual 1, and gradual 2 groups, respectively.
Mean (± SD) modal doses of risperidone over the entire 6-
week study period were 4.2 (± 1.4), 4.6 (± 1.4), and 4.1 (±
1.4) mg/day in the three groups.
The most common concomitant medications initiated
during the study were sedative/hypnotic drugs in 12
(30%), 12 (30%), and 9 (21%) patients in the abrupt,
gradual 1, and gradual 2 groups, respectively (p = 0.0145,
abrupt versus gradual 2; chi-square test). Antiparkinson-
ism drugs were received by two (5%), two (5%), and three
(7%) patients in the three groups.
Efficacy
In this 6-week study, improvements in PANSS scores were
seen in each of the three groups of patients (Table 3, Fig-
ure 2). In the abrupt group, significant improvements
from baseline to endpoint were seen in PANSS total scores
and scores on the positive and anxiety/depression sub-
scales (Figure 3). In the gradual 1 group, a significant
improvement from baseline to endpoint was seen only in
PANSS positive scores. In the gradual 2 group, significant
improvements from baseline to endpoint were seen in all
evaluated PANSS domains. Moreover, at week 1 a signifi-
cant improvement in the PANSS total score was noted
only in the gradual 2 group (p = 0.0022); see Figure 2.
Between-group comparisons were not statistically signifi-
cant.
The proportions of patients who were improved on the
CGI-C at endpoint were 50%, 44%, and 54% in the
abrupt, gradual 1, and gradual 2 groups, respectively.
Patients who were worse at endpoint included 22%, 26%,
and 13% of the abrupt, gradual 1, and gradual 2 groups,
respectively. The proportions of patients with no symp-
toms or slight or mild symptoms on the CGI-S scale were
38% of the abrupt group, 47% of the gradual 1 group, and
40% of the gradual 2 group at baseline, and 64%, 44%,
and 67%, respectively, at endpoint. Between-group differ-
ences in CGI scores were not significant.
The GAF scores improved significantly from baseline to
endpoint in the abrupt, gradual 2, and pooled treatment
groups, but not in the gradual 1 group. Mean (± SD)
changes in GAF scores at endpoint were 4.3 (± 7.5; p =
0.0016), 0.0 (± 9.6; p = NS), and 3.6 (± 10.8; p = 0.0449)
in the abrupt, gradual 1, and gradual 2 treatment groups,
respectively. Between-group comparisons were not signif-
icant at endpoint.
The mean DAI-10 scores were reduced in the abrupt group
from baseline to endpoint and improved significantly in
the gradual 2 group, in whom the mean (± SD) change at
endpoint was 1.3 (± 3.2; p = 0.0120). Between-group dif-
ferences were not significant.
Safety
Adverse events were generally reported to be mild.
Adverse events were reported in 73%, 90%, and 79% of
the abrupt, gradual 1, and gradual 2 groups, respectively;
these were mild or moderate in 93%, 89%, and 91% of
patients who experienced an adverse event. Adverse events
reported in at least 10% of patients in any treatment group
Table 2: Baseline patient demographic and clinical characteristics
Abrupt (n = 37) Gradual 1 (n = 39) Gradual 2 (n = 40)
Sex, % female 51 51 50
Race/ethnicity, %
White 57 54 53
Black 32 31 33
Hispanic 5 13 8
Asian 5 3 5
Age, mean (± SD) years 41.6 (± 10.2) 41.5 (± 10.4) 40.3 (± 9.1)
BMI, mean (± SD) kg/m2 36.2 (± 9.1) 34.0 (± 6.2) 32.3 (± 4.7)
Diagnosis, %
Schizophrenia 57 56 53
Schizoaffective disorder 43 44 47
Olanzapine dose, mean (± SD) mg/day 14.4 (± 5.4) 15.5 (± 6.3) 16.4 (± 7.9)BMC Medicine 2008, 6:17 http://www.biomedcentral.com/1741-7015/6/17
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were insomnia, anxiety, sedation, somnolence, headache,
and aggravated psychosis (Table 4). The overall between-
group difference in the incidence of aggravated psychosis
was significant (p = 0.0483, exact test). The incidence of
movement disorders was low in the three treatment
groups throughout the 6-week study. Discontinuation
because of an adverse event was reported in 5%, 15%, and
5% in the abrupt, gradual 1, and gradual 2 groups, respec-
tively (Table 1). Discontinuations because of adverse
events during the first 2-week transition period were low
in all three study groups, with one each in the abrupt and
gradual 2 groups and two in the gradual 1 group. The inci-
Table 3: Mean (± SD) baseline and changes at endpoint in PANSS total, positive, negative, and anxiety/depression scores in the three 
groups of patients.
PANSS Abrupt (n = 29) Gradual 1 (n = 34) Gradual 2 (n = 31) All Groups (n = 94) Between-treatment p-valuea
Total
Baseline 74.6 (± 10.6) 76.0 (± 12.3) 76.2 (± 11.6) 75.6 (± 11.5)
Change -7.5 (± 14.4)† -4.9 (± 17.1) -9.8 (± 15.1)‡ -7.3 (± 15.6)‡ 0.1497
Positive
Baseline 21.7 (± 4.2) 23.1 (± 5.2) 21.1 (± 5.5) 22.0 (± 5.1)
Change -3.4 (± 4.6)‡ -2.6 (± 6.4)* -3.0 (± 4.9)† -3.0 (± 5.4)‡ 0.2009
Negative
Baseline 17.9 (± 4.8) 18.1 (± 5.2) 19.5 (± 5.7) 18.5 (± 5.2)
Change -0.7 (± 6.0) 0.2 (± 6.2) -2.2 (± 5.8)* -0.9 (± 6.1) 0.2904
Anxiety/depression
Baseline 11.1 (± 3.4) 10.3 (± 3.6) 10.9 (± 3.4) 10.7 (± 3.5)
Change -1.6 (± 3.6)* -0.5 (± 3.6) -2.2 (± 3.9)† -1.4 (± 3.7)‡ 0.618
aFrom an analysis of covariance (ANCOVA) model with treatment, site, and baseline value as factors.
*p < 0.05, †p < 0.01, ‡p < 0.001 versus baseline (paired t-test).
Improvements in PANSS total scores from baseline to endpoint in the three treatment groups Figure 2
Improvements in PANSS total scores from baseline to endpoint in the three treatment groups.
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dence of movement disorders was low in all three groups
during the first 2 weeks, with one report in each group.
No significant changes from baseline to week 6 or end-
point were seen in vital signs, body weight, or anthropo-
metric measurements in any treatment group, with the
exception of a significant reduction in mean standing
diastolic blood pressure at week 6 and endpoint in the
abrupt group only (-6.6 mmHg at week 6, p = 0.005; and
-5.5 mmHg at endpoint, p = 0.0167; paired t-test). In the
gradual 1 and 2 groups the respective values were -1.6 and
0.1 mmHg and 2.2 and 2.2 mmHg.
Significant improvements from baseline to endpoint in
levels of total cholesterol (-8.22 mg/dl; p = 0.0075), very-
low-density lipoprotein (-4.11 mg/dl; p = 0.0359), apoli-
poprotein A1 (-4.32 mg/dl; p = 0.0372), apolipoprotein B
(-8.42 mg/dl; p < 0.0001), and triglycerides (-20.5 mg/dl;
Mean changes from baseline in PANSS total and subscale scores Figure 3
Mean changes from baseline in PANSS total and subscale scores.
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Table 4: Adverse events reported in at least 10% of patients in any treatment group.
Abrupt (n = 40) Gradual 1 (n = 39) Gradual 2 (n = 42) All treatments (n = 121)
Patients with any adverse event 73% 90 % 79% 80%
Insomnia 23% 13% 24% 20%
Anxiety 18% 13% 14% 15%
Sedation 5% 18% 12% 12%
Somnolence 10% 10% 10% 10%
Headache 3% 10% 7% 7%
Aggravated psychosis 13% 0 5 6%BMC Medicine 2008, 6:17 http://www.biomedcentral.com/1741-7015/6/17
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p = 0.0364) were seen in the pooled patient group (paired
t-test). These data have been discussed in more detail else-
where [11].
Behavioral therapy for weight loss and the metabolic 
syndrome (phase 2)
After participating in the 6-week study of switching strate-
gies (phase 1), all patients with a BMI above 26 kg/m2
were invited to enroll in a weight-loss program while
receiving risperidone [10]. Seventy-one consenting sub-
jects were randomly assigned to 14 weeks of a behavioral
treatment program for weight reduction (n = 34) or usual
clinic care (n = 37). After 14 weeks, significant weight loss
was reported in both treatment groups: mean (± SD)
changes were -2.0 ± 3.8 kg in the subjects enrolled in the
behavioral program and -1.1 ± 3.1 kg in the control group
(both  p  < 0.05). The significant reductions in PANSS
scores noted in the 6-week phase 1 were maintained dur-
ing the 14 weeks [10]. The mean modal doses of risperi-
done were 4.3 mg/day at the end of phase 1 and 4.5 mg/
day during phase 2.
In the 71 patients for whom data were available for both
phases, the incidence of the metabolic syndrome was sig-
nificantly reduced over the 20-week period [11]. The syn-
drome was identified in 38 (54%) of the patients at
baseline and in 26 (37%) at the end of phase 2 (p  <
0.0001). Significant reductions (p < 0.05) were also seen
in mean (± SD) weight (-1.3 ± 4.9 kg), BMI (-0.7 ± 1.7 kg/
m2), waist circumference (-1.6 ± 5.6 cm), and systolic (-
4.7 ± 14.0 mmHg) and diastolic (-3.5 ± 11.0 mmHg)
blood pressure [11].
Discussion
In overweight/obese patients who had shown a poor
response to treatment with olanzapine, the strategy
involving the slowest dose reduction of previous medica-
tion (gradual 1) was associated with the highest rates of
retention ('successful switching') compared with the other
two strategies. Twelve percent of the gradual 1 group dis-
continued treatment prematurely, compared with 25% of
the patients in the abrupt group and 28% in the gradual 2
group. The three methods of switching to risperidone
were generally associated with improvements in symp-
toms and were relatively well tolerated.
Although improvements on the PANSS scale were noted
in all three treatment groups, some differences in patterns
of response were noted. Patients in the gradual 2 group
showed significant improvements in PANSS total scores
as early as week 1 (Figure 2) and significant improvements
in scores on each of the three PANSS subscales (Figure 3).
Patients in the abrupt group showed significant improve-
ments in PANSS total scores and scores on two subscales,
while patients in the gradual 1 group showed significant
improvement on only one subscale. Between-group dif-
ferences, however, were not significant.
Adverse events were generally mild. Some events that
resemble withdrawal symptoms (nausea, vomiting, agita-
tion, movement disorders) were reported. Except for anx-
iety, however, the incidence of such symptoms was low,
and the time-course of these events did not clearly suggest
olanzapine withdrawal as a cause. Nonetheless, some of
the differences between treatment groups might be attrib-
uted to the different withdrawal schedules. The incidence
of aggravated psychosis was highest in the abrupt group
(13% versus 0% and 5% in the gradual 1 and gradual 2
groups, respectively), as would be consistent with abrupt
withdrawal of an antipsychotic before optimum levels of
the other antipsychotic are reached. A similar pattern was
seen in the incidence of anxiety, although the differences
were less marked (18% in the abrupt group versus 13%
and 14% in the other two groups). In addition, the reduc-
tion in mean standing diastolic blood pressure reported
only in the abrupt group may have been due to choliner-
gic rebound associated with abrupt withdrawal of olanza-
pine.
The incidence of study discontinuation due to adverse
events was highest in the gradual 1 group (15% versus 5%
in each of the other groups). It is unclear why a lower rate
of discontinuation was not observed in the gradual 1
group, with more gradual discontinuation of olanzapine,
than in the abrupt group, particularly as this strategy of
brief overlap in treatments may be the most commonly
used in clinical practice. The incidence of discontinuation
due to withdrawal of consent was 0 in the gradual 2 group
and 8% and 10% in the abrupt and gradual 1 groups,
respectively.
Anxiety/depression and positive and total symptoms were
improved when switching these patients from olanzapine
to risperidone. The overall findings suggest that all three
tested strategies of switching to risperidone would be rea-
sonable approaches in patient care. However, the small
group sample sizes make it hard to draw conclusions
about individual strategies, especially when a consistent
trend is not observed with increasingly gradual discontin-
uation of prior treatment. Thus, the apparent better effi-
cacy and retention observed in the gradual 2 group is of
uncertain significance. Further studies may be necessary to
determine whether these apparent subtle differences
between switch strategies persist over time and with a
larger sample.
Our study was limited by its open-label design, although
possible bias was mitigated by the fact that raters were
blind to the switch strategy. Phase 1 of the study was also
limited by its short duration, such that long-term effects ofPublish with BioMed Central    and   every 
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switching were not assessed. Further, switch strategies
employed in the clinical practice setting often vary the
duration of switch based upon the needs of the individual
patient, and the current study was limited due to study-
blinding procedures.
Conclusion
Our study confirms that stable outpatients with schizo-
phrenia or schizoaffective disorder who require an alter-
native treatment can be safely switched from olanzapine
to risperidone and experience improvements in symptom
control. Our results also suggest that rapid initiation of
the new medication and very gradual withdrawal of the
old medication may be more successful than more rapid
withdrawal strategies.
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